Market Applicability														
Market	**DC**	**FL & FHK**	**FL MMA**	**FL LTC**	**GA**	**KS**	**KY**	**MD**	**NJ**	**NV**	**NY**	**TN**	**TX**	**WA**
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Avastin (bevacizumab)

CG-DRUG-68, CG-DRUG-90

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Avastin (bevacizumab)

APPROVAL CRITERIA

Requests for Avastin (bevacizumab) may be approved when the following criteria are met:

I. Individual is being treated for ANY of the following:
   A. Diabetic macular edema; **OR**
   B. Proliferative diabetic retinopathy with or without diabetic macular edema; **OR**
   C. Established neovascular "wet" age-related macular degeneration; **OR**
   D. Macular edema from branch retinal vein occlusion; **OR**
   E. Macular edema from central retinal vein occlusion; **OR**
   F. Neovascular glaucoma; **OR**
   G. Other rare causes of choroidal neovascularization for one or more of the following conditions:
      1. Angioid streaks; **OR**
      2. Choroiditis (including, but not limited to histoplasmosis induced choroiditis); **OR**
      3. Degenerative myopia (idiopathic); **OR**
      4. Retinal dystrophies; **OR**
      5. Trauma; **OR**
   H. Pseudoxanthoma elasticum; **OR**
   I. Radiation retinopathy; **OR**
   J. Retinopathy of prematurity;

OR

II. Breast Cancer:
   A. In the treatment of individuals with metastatic breast carcinoma when all of the following criteria are met:
      1. HER2-negative breast cancer; **AND**

Market Applicability														
Market	**DC**	**FL & FHK**	**FL MMA**	**FL LTC**	**GA**	**KS**	**KY**	**MD**	**NJ**	**NV**	**NY**	**TN**	**TX**	**WA**
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

2. Used in first-line chemotherapy* for treatment of metastatic disease; **AND**
3. Used in combination with paclitaxel or paclitaxel protein-bound;

*Note: Hormonal therapy alone is not considered "chemotherapy."

OR

III. Central Nervous System – Primary Tumor:

A. In the treatment of individuals with a primary central nervous system tumor who have failed radiation therapy when the following criteria are met:
   1. Avastin is being used in a single line of therapy; **AND**
   2. The tumor to be treated is a World Health Organization (WHO) Grade III/IV glioma (includes, but is not limited to):
      a. Anaplastic astrocytoma; **OR**
      b. Anaplastic glioma; **OR**
      c. Ependymoma, progressive or recurrent; **OR**
      d. Glioblastoma; **OR**
      e. Glioblastoma multiforme; **OR**
      f. High-grade glioma, recurrent;

OR

IV. Cervical Cancer:

A. In the treatment of individuals with metastatic cervical cancer when all of the following criteria are met:
   1. Individual has recurrent, or persistent disease that is not amenable to curative treatment with surgery or radiotherapy; **AND**
   2. Avastin is being used in combination with paclitaxel and topotecan, or with paclitaxel and cisplatin chemotherapy; **AND**
   3. Avastin is being used in a single line of therapy;

OR

V. Colon, Rectal, Colorectal and Small Bowel Adenocarcinoma:

A. In the treatment of individuals with metastatic colon, rectal, colorectal, or small bowel adenocarcinoma when the following criteria are met:
   1. Avastin is being used in combination with 5FU-based chemotherapy, irinotecan or oxaliplatin; **AND**
   2. Individual has not progressed on more than two lines of a bevacizumab-containing chemotherapy agent;

Market Applicability														
Market	**DC**	**FL & FHK**	**FL MMA**	**FL LTC**	**GA**	**KS**	**KY**	**MD**	**NJ**	**NV**	**NY**	**TN**	**TX**	**WA**
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

OR

VI. Endometrial Carcinoma:

A. In the treatment of individuals with advanced or recurrent endometrial carcinoma when the following are met:
   1. Avastin is being used in combination with carboplatin and paclitaxel; **OR**
   2. Following combination therapy with carboplatin and paclitaxel, Avastin is being used as single-agent maintenance therapy until disease progression or prohibitive toxicity;

OR

VII. Malignant Mesothelioma:

A. In the treatment of individuals with unresectable malignant mesothelioma when the following criteria are met:
   1. Avastin is being used in a first-line combination chemotherapy with cisplatin or carboplatin **and** pemetrexed; **AND**
   2. Individual has an Eastern Cooperative Oncology Group performance status of 0-2 and no history of bleeding or thrombosis;

OR

B. As maintenance therapy in the treatment of individuals with unresectable malignant mesothelioma when all of the following criteria are met:
   1. Avastin was previously administered as an agent in a first-line combination chemotherapy regimen; **AND**
   2. Avastin is being used as a single agent; **AND**
   3. Avastin is being used until disease progression*;

   *Note: Once disease progression has occurred, bevacizumab is not to be re-instituted.

OR

VIII. Non-Small Cell Lung Cancer:

A. As a first-line treatment of non-squamous, non-small cell lung cancer (NSCLC) when an individual has a current Eastern Cooperative Oncology Group performance status of 0-1, no history of hemoptysis, and the following criteria are met:
   1. Avastin is being used for unresectable, locally advanced, recurrent or metastatic disease in combination chemotherapy with platinum-based therapy and a taxane or pemetrexed; **OR**
   2. Avastin is being used for recurrent or metastatic disease in combination chemotherapy with platinum-based therapy, a taxane, and atezolizumab;

Market Applicability														
Market	**DC**	**FL & FHK**	**FL MMA**	**FL LTC**	**GA**	**KS**	**KY**	**MD**	**NJ**	**NV**	**NY**	**TN**	**TX**	**WA**
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

OR

B. As maintenance therapy in the treatment of an individual with non-squamous NSCLC when Avastin was previously administered as an agent in first-line combination chemotherapy regimen, is used until disease progression, and the following criteria are met:
   1. Avastin is being used for unresectable, locally advanced, recurrent or metastatic disease as a single agent; **OR**
   2. Avastin is being used for recurrent or metastatic disease as a single agent or in combination with atezolizumab;

OR

IX. Ovarian Cancer:

A. In the treatment of individuals with recurrent, metastatic epithelial ovarian cancer, fallopian tube cancer or recurrent primary peritoneal cancer when all of the following criteria are met:
   1. Avastin is being used as a single agent or in combination with other chemotherapy; **AND**
   2. Avastin is being used in a single line of therapy; **AND**
   3. Avastin is being used for relapsed or refractory disease;

OR

B. In the treatment of individuals with advanced or metastatic epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection when the following criteria are met:
   1. Avastin is being used in combination with other chemotherapy; **AND**
   2. Avastin is being used in a single line of therapy;

OR

C. As maintenance therapy in individuals with recurrent, metastatic epithelial ovarian cancer, fallopian tube cancer or recurrent primary peritoneal cancer when all of the following criteria are met:
   1. Avastin was previously administered as an agent in a first-line combination chemotherapy regiment; **AND**
   2. Avastin is being used as a single agent; **AND**
   3. Avastin may be used until disease progression;

OR

Market Applicability														
Market	**DC**	**FL & FHK**	**FL MMA**	**FL LTC**	**GA**	**KS**	**KY**	**MD**	**NJ**	**NV**	**NY**	**TN**	**TX**	**WA**
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

D. In the treatment of individuals with advanced or metastatic epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection when the following criteria are met:
   1. Avastin was previously administered as an agent in a combination chemotherapy regimen following surgical resection; **AND**
   2. Avastin is being used as a single agent; **AND**
   3. Avastin may be used until disease progression;

OR

X. Post-Radiation Necrosis:
   A. In the treatment of individuals with symptomatic post-radiation necrosis of the central nervous system;

OR

XI. Renal Cell Carcinoma:
   A. In the treatment of individuals with renal carcinoma (RCC) when the following criteria are met:
      1. Avastin is being used in first-line treatment of metastatic clear cell RCC in combination with interferon; **OR**
      2. Avastin is being used as a single agent for relapsed or medically unresectable stage IV disease with predominant clear cell histology in individuals who have progressed on prior cytokine therapy; **OR**
      3. Avastin is being used as a single agent for relapsed or medically unresectable stage IV disease with non-clear-cell histology; **OR**
      4. Avastin is being used for relapsed or medically unresectable stage IV non-clear cell RCC (including papillary RCC and hereditary leiomyomatosis and RCC [HLRCC]), in combination with erlotinib or everolimus;

OR

XII. Soft Tissue Sarcoma:
   A. In the treatment of individuals with angiosarcoma **AND** is Avastin is being used as a single agent; **OR**
   B. In the treatment of individuals with solitary fibrous tumor and hemangiopericytoma and individual is using Avastin in combination with temozolomide.

Avastin (bevacizumab) may **not** be approved in the treatment of all other conditions when the criteria above are not met, including but not limited to any of the following:

I. Adjuvant therapy following surgery for stage II or III adenocarcinoma of the colon; **OR**
II. Prostate cancer; **OR**

Market Applicability														
Market	**DC**	**FL & FHK**	**FL MMA**	**FL LTC**	**GA**	**KS**	**KY**	**MD**	**NJ**	**NV**	**NY**	**TN**	**TX**	**WA**
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

III. Carcinoid tumors; **OR**
IV. Metastatic melanoma; **OR**
V. Metastatic adenocarcinoma of the pancreas; **OR**
VI. Metastatic breast cancer, second line therapy or greater, for example when progression noted following anthracycline and taxane chemotherapy; **OR**
VII. Neurofibromatosis type 2; **OR**
VIII. Treatment of a single condition with concomitant Avastin (bevacizumab) use with other targeted biologic agents (including but not limited to erlotinib, cetuximab, panitumumab, trastuzumab, lapatinib and ziv-aflibercept)**; OR**
IX. When used in combination with the same irinotecan based regimen that was previously used in combination with ziv-aflibercept.

Note: Avastin (bevacizumab) has black box warnings for gastrointestinal perforations, surgery and wound healing complications, and hemorrhage.
Gastrointestinal Perforations: The incidence of gastrointestinal perforation, some fatal, in patients receiving Avastin ranges from 0.3 to 3.2%. Discontinue Avastin in patients who develop gastrointestinal perforation.
Surgery and Wound Healing Complications: The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in patients receiving Avastin. Discontinue Avastin in patients with wound dehiscence. The appropriate interval between termination of Avastin and subsequent elective surgery required to reduce the risks of impaired healing/wound dehiscence has not been determined. Discontinue at least 28 days prior to elective surgery. Do not initiate Avastin for at least 28 days after surgery and until the surgical wound is fully healed.
Hemorrhage: Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, hematemesis, central nervous system (CNS) hemorrhage, epistaxis, and vaginal bleeding occurred up to 5-fold more frequently in patients receiving Avastin. Do not administer Avastin to patients with a recent history of hemoptysis. Discontinue in patients who develop Grade 3-4 hemorrhage.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Market Applicability														
Market	**DC**	**FL & FHK**	**FL MMA**	**FL LTC**	**GA**	**KS**	**KY**	**MD**	**NJ**	**NV**	**NY**	**TN**	**TX**	**WA**
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Key References:

1. American Hospital Formulary Service® (AHFS). AHFS Drug Information 2018®. Bethesda, MD. American Society of Health-System Pharmacists®; 2018.
2. Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014;(11):CD008721.
3. Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2018;(2):CD009734.
4. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2015;(8):CD008214.
5. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;(8):CD005139.
6. Avastin [Product Information]. South San Francisco, CA. Genentech, Inc.; June 2018. Available at: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed on June 18, 2018.
7. Azzoli C, Baker S, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for Stage IV non-small-cell lung cancer. J Clin Oncol. 2009; 27(36):6251-6266.
8. Bevacizumab. In: DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated May 16, 2018. Available at: http://www.micromedexsolutions.com. Accessed on June 18, 2018.
9. Bevacizumab Monograph. Lexicomp® Online, American Hospital Formulary Service® (AHFS®) Online, Hudson, Ohio, Lexi-Comp., Inc. Last revised September 22, 2016. Accessed on June 18, 2018.
10. Irshad T, Olencki T, Zynger DL, et al. Bevacizumab in metastatic papillary renal cell carcinoma (PRCC) [abstract]. J Clin Oncol. 2011; 29:e15158.
11. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neurophathol. 2007; 114(2):97-109.
12. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015; 33(30):3488-3515.
13. NCCN Clinical Practice Guidelines in Oncology®. © 2018 National Comprehensive Cancer Network, Inc. For additional information: http://www.nccn.org/index.asp. Accessed on June 28, 2018.
    - Breast Cancer (V1.2018). Revised March 20, 2018.
    - Central Nervous System Cancers (V1.2018). Revised March 20, 2018.
    - Cervical Cancer (V1.2018). Revised October 17, 2017.
    - Colon Cancer (V2.2018). Revised March 14, 2018.
    - Hepatobiliary Cancers (V2.2018). Revised June 7, 2018.
    - Kidney Cancer (V4.2018). Revised April 23, 2018.
    - Malignant Pleural Mesothelioma (V2.2018). Revised February 26, 2018.
    - Melanoma (Cutaneous) (V2.2018). Revised January 19, 2018.
    - Non-Small Cell Lung Cancer (V5.2018). Revised June 27, 2018.
    - Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (V2.2018). Revised March 9, 2018.
    - Pancreatic Adenocarcinoma (V1.2018). Revised April 27, 2018.
    - Prostate Cancer (V3.2018). Revised June 21, 2018.
    - Rectal Cancer (V2.2018). Revised June 27, 2018.
    - Soft Tissue Sarcoma (V2.2018). Revised March 27, 2018.
    - Uterine Neoplasms (V2.2018). Revised May 25, 2018.

Market Applicability														
Market	**DC**	**FL & FHK**	**FL MMA**	**FL LTC**	**GA**	**KS**	**KY**	**MD**	**NJ**	**NV**	**NY**	**TN**	**TX**	**WA**
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

14. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e341S-e368S.
15. U.S. Food and Drug Administration Drug Safety and Awareness. Updated November 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm193900.htm. Accessed on June 18, 2018.
16. Van Gompel JJ, Agazzi S, Carlson ML, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas. Neurosurgery. 2018; 82(2):E52-E54.